Royalty Pharma plc
RPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001802768
In the last 90 days, Royalty Pharma plc insiders filed 0 open-market purchases and 4 sales; 650 institutions reported holding it in 13F filings for Q2 2026, worth $20.6B in total; Dorsey Asset Management is the only superinvestor holding it.
Q3 2025 vs. Q2 2025
How the institutions holding Royalty Pharma plc changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 458 | 7 | 490 | +39 |
| Shares | 342.7M | 5.11M | 328.9M | −8.75M (−2.6%) |
| Value | $12.4B | $184.3M | $11.6B | −$571.2M (−4.7%) |
7 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (91)
Institutions that held Royalty Pharma plc at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (52)
Institutions that held Royalty Pharma plc at the end of Q2 2025 and filed for Q3 2025 without it.
Not filed for Q3 2025 yet (7)
Institutions that held Royalty Pharma plc at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Norges Bank | 5,034,369 | $181.4M |
| Graypoint LLC | 35,192 | $1.27M |
| Avantax Advisory Services, Inc. | 15,793 | $569.0K |
| CIBC World Markets Corp | 15,342 | $552.8K |
| EP Wealth Advisors, LLC | 9,314 | $335.6K |
| Atlas Capital Advisors LLC | 4,639 | $167.1K |
| First Horizon Advisors, Inc. | 60 | $2.16K |